Skip to main content
. 2018 Sep 20;103(12):2088–2096. doi: 10.3324/haematol.2018.194282

Figure 3.

Figure 3.

PFS by MRD at sensitivity threshold of (A) 10−5 and (B) 10−6. Kaplan-Meier estimates of PFS among patients in the intent-to-treat population. MRD-negative status was evaluated at sensitivity thresholds of 10−5 and 10−6 using bone marrow aspirate samples that were prepared using Ficoll and analyzed by the clonoSEQTM assay. PFS: progression-free survival; MRD: minimal residual disease; D-Rd: daratumumab/lenalidomide/dexamethasone; Rd: lenalidomide/dexamethasone.